From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Amryt Pharma – placing disappointment, my anger as a shareholder, CEO chat - BUY

By Tom Winnifrith | Saturday 23 September 2017


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


With its shares having reached 25.75p last week and closed at above 25p on Wednesday, Amryt Pharma (AMYT) announced on Thursday that it was “delighted with the support we have received” for an “oversubscribed placing”, raising a gross €15 million (£13.3 million)… at 20p per share! As a long standing shareholder I say "F**k you." I feel so utterly 100% shafted as will those who paid 26p+ last week after confident results which made it clear that Amryt was fully funded. So I asked Steve Moore to pen an analysis. As I explained in Thursday's bearcast HERE I am too angry to be objective. The fact is that at a 22.5p offer the shares are a BUY.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ANP

Anpario – a recovery Buy?...

Thursday »

Cat_Fixing_Lightbulb

Bearcast issue update: all should be well

 

ORCP

Oracle Power: Cynical Foul

Time left: 16:17:50